NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

AMF - Amorfix Life Sciences Ltd

Amorfix Life Sciences Ltd. (Amorfix) is an emerging theranostics company focused on the diagnosis and treatment of diseases, where aggregated misfolded proteins (AMP) are prevalent. These include transmissible spongiform encephalopathies (TSE), such as bovine spongiform encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases, such as Alzheimer","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

AMF Chart

Amorfix Life Sciences Ltd News


Today's small-cap stocks to watch
Globe and Mail - May 16, 2012
VoodooVox Inc. VVX-T, which dropped 21 per cent at yesterday's close, announced today its financial results for the three months ended March 31, 2012.

Amorfix Develops Antibodies Binding To MFR Protein As Potential Cancer Treatment
NASDAQ - May 15, 2012
(RTTNews.com) - Amorfix Life Sciences Ltd. (AMF.TO) announced Tuesday that it has developed antibodies that selectively target and bind to misfolded Fas receptor protein expressed on the cell surface of cancer cells.
Amorfix Closes Private Placement Offering - Canada NewsWire (press release)

Amorfix Announces the Development of Antibodies that Bind to Misfolded Fas ...
Canada NewsWire (press release) - May 15, 2012
TORONTO, May 15, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that the Company has developed antibodies that selectively target and bind to misfolded Fas receptor protein expressed on the cell surface of cancer cells.

Amorfix Life Sciences Ltd. Closes Private Placement Offering
Reuters Key Development - May 14, 2012

Amorfix Life Sciences to Raise Up to $1 Million
TechFinance - May 9, 2012
Amorfix Life Sciences Ltd. (TSX: AMF), a developer of therapeutic antibodies and diagnostics targeting cancer and amyotrophic lateral sclerosis (ALS), said it intends to complete a non-brokered private placement of up to 2500000 units priced at $0.40 ...
Amorfix Announces Private Placement - Canada NewsWire (press release)

Amorfix Life Sciences Ltd. Announces Private Placement
Reuters Key Development - May 8, 2012

Amorfix To Collaborate With World Leader In Prion Diagnostic Research
4-traders - May 2, 2012
AMORFIX TO COLLABORATE WITH WORLD LEADER IN PRION DIAGNOSTIC RESEARCH TORONTO, Ontario - May 1, 2012 - Amorfix Life Sciences Ltd. announced today that the Company has established a collaboration with Dr.

Amorfix Life Sciences and Dr. Detlev Riesner to Collaborate in Prion ...
TechFinance - May 1, 2012
Amorfix Life Sciences Ltd. (TSX: AMF) said it has entered into a collaboration agreement with Dr. Detlev Riesner of the Heinrich-Heine-University in Düsseldorf Germany, a world leader in prion diagnostics, in a new blood test for animal prion infection ...

Today's small-cap stocks to watch
Globe and Mail - May 1, 2012
Mercer International Inc. MRI.UTabandoned its battle with AbitibiBowater Inc. ABH-T for control of pulp maker Fibrek Inc. FBK-T. Advantage Oil & Gas Ltd.

Amorfix Life Sciences Ltd. Acquires SOD1 Technology And Provides Update On Financing
Reuters Key Development - Mar 12, 2012

TSX Media Coverage Selection of the best articles found in your favorit medias

Next Company >>